Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme

被引:43
|
作者
Rahnasto, M
Raunio, H
Poso, A
Wittekindt, C
Juvonen, RO
机构
[1] Univ Kuopio, Dept Pharmacol & Toxicol, FIN-70211 Kuopio, Finland
[2] Univ Kuopio, Dept Pharmaceut Chem, FIN-70211 Kuopio, Finland
关键词
D O I
10.1021/jm049536b
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was to develop screening and in silico modeling methods to obtain accurate information on the active center of CYP2A6, a nicotine oxidizing enzyme. The inhibitory potencies of 26 naphthalene and 16 non-naphthalene derivatives were determined for human CYP2A6 and mouse CYP2A5 enzymes. Several comparative molecular field analysis (CoMFA) models were developed to find out what types of steric and electrostatic properties are required for potent inhibitors. The IC50 values of the tested compounds varied from 0.55 to 35 400 muM for CYP2A6 and from 1 to 1500 muM for CYP2A5. The generated CoMFA models were able to accurately predict the inhibition potencies of an external test set of chemicals. Potent and specific inhibitors of the CYP2A6 enzyme can be used in the future to increase nicotine bioavailability and thus make oral nicotine administration feasible in smoking cessation therapy.
引用
收藏
页码:440 / 449
页数:10
相关论文
共 50 条
  • [1] Cinnamaldehyde Analogs as CYP2A6 Inhibitors: A Structure-Activity Study
    Black, Stephen
    Joseph, Paul
    Higa, Allyson
    Moyeen, Ghina
    Ebisuya, Kara
    Davis, Madison
    Chan, Jeannine
    Harrelson, John
    FASEB JOURNAL, 2016, 30
  • [2] Quantitative structure-activity relationship to elucidate human CYP2A6 inhibition by organosulfur compounds
    Ramirez, Daniela A.
    Marchevsky, Eduardo J.
    Luco, Juan M.
    Camargo, Alejandra B.
    ADMET AND DMPK, 2019, 7 (03): : 196 - 209
  • [3] In silico development of inhibitors of the nicotine metabolising CYP2A6 enzyme
    Rahnasto, M
    Poso, A
    Raunio, H
    Juvonen, RO
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2004, 197 (03) : 285 - 285
  • [4] Conceptual DFT Properties-Based 3D QSAR: Analysis of Inhibitors of the Nicotine Metabolizing CYP2A6 Enzyme
    Van Damme, Sofie
    Bultinck, Patrick
    JOURNAL OF COMPUTATIONAL CHEMISTRY, 2009, 30 (12) : 1749 - 1757
  • [5] Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme -: an in silico approach
    Rahnasto, M.
    Wittekindt, C.
    Juvonen, R. O.
    Turpeinen, M.
    Petsalo, A.
    Pelkonen, O.
    Poso, A.
    Stahl, G.
    Holtje, H-D
    Raunio, H.
    PHARMACOGENOMICS JOURNAL, 2008, 8 (05): : 328 - 338
  • [6] Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme—an in silico approach
    M Rahnasto
    C Wittekindt
    R O Juvonen
    M Turpeinen
    A Petsalo
    O Pelkonen
    A Poso
    G Stahl
    H-D Höltje
    H Raunio
    The Pharmacogenomics Journal, 2008, 8 : 328 - 338
  • [7] Impact of E-Cigarette Liquid Flavoring Agents on Activity of Microsomal Recombinant CYP2A6, the Primary Nicotine-Metabolizing Enzyme
    Winters, Brett R.
    Kochar, Tavleen K.
    Clapp, Phillip W.
    Jaspers, Ilona
    Madden, Michael C.
    CHEMICAL RESEARCH IN TOXICOLOGY, 2020, 33 (07) : 1689 - 1697
  • [8] Three-dimensional quantitative structure-activity relationship (3D-QSAR), analysis of CYP2B6 enzyme
    Raunio, Hamm
    Korhonen, Laura
    Turpeinen, Miia
    Ralmasto, Minna
    Wittekindt, Carsten
    Poso, Antti
    Juvonen, Risto
    TOXICOLOGY LETTERS, 2006, 164 : S66 - S66
  • [9] Dihydroorotate Dehydrogenase Inhibitors: Quantitative Structure-activity Relationship Analysis
    Shijun Ren
    Sharon K. Wu
    Eric J. Lien
    Pharmaceutical Research, 1998, 15 : 286 - 295
  • [10] Dihydroorotate dehydrogenase inhibitors: Quantitative structure-activity relationship analysis
    Ren, SJ
    Wu, SK
    Lien, EJ
    PHARMACEUTICAL RESEARCH, 1998, 15 (02) : 286 - 295